Evidence map›Paper›PMID 38856821›Full record

ArticleJournal of neurovirology2024

CD4 nadir and neurocognitive trajectories in people living with HIV.

Razmig Garabet, Will Dampier, Shinika Tillman, Kim Malone, Zsofia Szep, Amy Althoff, Vanessa Pirrone, Michael R Nonnemacher, Brian Wigdahl, Maria Schultheis and 1 more

Abstract read
In one paragraph

Article in Journal of neurovirology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Incidence of dementia after a recent cancer diagnosis among people with HIV.medRxiv : the preprint server for health sciences · 2026
    Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Razmig GarabetDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.
Will DampierDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.
Shinika TillmanCenter for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USA.
Kim MaloneCenter for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USA.
Zsofia SzepDivision of Infectious Diseases, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Amy AlthoffDepartment of Medicine, Division of Infectious Diseases and HIV Medicine, Drexel University, Philadelphia, PA, USA.
Vanessa PirroneDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.
Michael R NonnemacherDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.
Brian WigdahlDepartment of Microbiology and Immunology, Drexel University College of Medicine, Philadelphia, PA, USA.
Maria SchultheisDepartment of Psychological and Brain Sciences, Drexel University, Philadelphia, PA, USA.
Kathryn N DevlinDepartment of Psychological and Brain Sciences, Drexel University, Philadelphia, PA, USA. knd52@drexel.edu.

Funding

Viral Gene Editing and Bioinformatics Core for Institution # 269291P30MH092177 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Ilker Kudret Sariyer · 2011 to 2026
$24.9M
Interdisciplinary And Translational Research Training In NeurohivT32MH079785 · NIMH · TEMPLE UNIV OF THE COMMONWEALTH · PI Kamel Khalili · 2008 to 2026
$5.4M
NIMH NIH HHS P30 MH092177NIMH NIH HHS T32 MH079785NIMH P30 MH092177NIMH T32 MH079785
6 · The paper itself

Abstract

Human immunodeficiency virus-associated neurocognitive disorders persist in the combination antiretroviral therapy era. CD4 nadir is a well-established predictor of cognition cross-sectionally, but its impact on longitudinal neurocognitive (NC) trajectories is unclear. The few studies on this topic examined trajectories of global cognition, rather than specific NC domains. The current study examined CD4 nadir in relation to domain-specific NC decline. 132 HIV + adults from the Temple/Drexel Comprehensive NeuroHIV Center, Clinical and Translational Research Support Core Cohort were administered comprehensive NC assessments longitudinally, with last visit occurring an average of 12 years after CD4 nadir. Linear mixed models were used to examine CD4 nadir in relation to longitudinal NC trajectories in three empirically identified NC domains: speed/executive function (S/EF), visuospatial memory (VM), and verbal fluency (VF). CD4 nadir was associated with change in VF (p = 0.020), but not with S/EF or VM. Specifically, those with CD4 nadir < 200 demonstrated increasing VF over time (p = .002), whereas those with CD4 nadir > 200 demonstrated stable VF (p = .568), though these differing trajectories may partly reflect regression to the mean or differential practice effect. CD4 dynamics over time were analyzed as potential mechanisms for the identified associations, with mixed findings. While low CD4 nadir has been associated with weaker neurocognition among people living with HIV, the results of this study suggest that low CD4 nadir is not associated with ongoing decline a decade later. Nadir-related deficits in VF may be stable or even improve over time, possibly reflecting the beneficial cognitive effects of long-term treatment and immune reconstitution.

Indexed as

HIV InfectionsAdultAIDS Dementia ComplexAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCognitionCognitive DysfunctionExecutive FunctionFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsAnti-HIV AgentsCD4 nadirHANDHIVLongitudinalNeurocognition

Identifiers

PMID38856821
PMCPMC11512832

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.